Ewing's sarcoma accounts for 10-15% of all primary malignant bone tumors,
and is the second in frequency among children. Until the introduction of the adjuvant chemotherapy
in the early sixties, the patients survival was lower than 10%. At present, all these patients
receive polychemotherapy combining a group of essential drugs: cyclophosphamide, iphosphamide,
vincristine, and actinomycine D. Patients survival has reached 70% of cases using niodern
therapeutic protocols. In our hospital, the 5-year actuarial survival rate was 64% in 27 children
less than 18-years-old. Patients with initially bad prognosis, having a lower survival rate, were
treated with megatherapy using high-dose chemotherapy, associated or not to total body radiation
and hematopoietic tem-cells rescue. Preliminary results are encouraging.

Ewing's sarcoma accounts for 10-15% of all primary malignant bone tumors,
and is the second in frequency among children. Until the introduction of the adjuvant chemotherapy
in the early sixties, the patients survival was lower than 10%. At present, all these patients
receive polychemotherapy combining a group of essential drugs: cyclophosphamide, iphosphamide,
vincristine, and actinomycine D. Patients survival has reached 70% of cases using niodern
therapeutic protocols. In our hospital, the 5-year actuarial survival rate was 64% in 27 children
less than 18-years-old. Patients with initially bad prognosis, having a lower survival rate, were
treated with megatherapy using high-dose chemotherapy, associated or not to total body radiation
and hematopoietic tem-cells rescue. Preliminary results are encouraging.